Chinese BioPharma Awards Minnesota Company Therapeutic Contract
MINNEAPOLIS--(BUSINESS WIRE)--Cell Culture Company (C3), a biopharmaceutical developer and
manufacturer, announced today it has entered into an agreement with a
China-based joint venture to produce a clinical-grade antibody-based
therapeutic vaccine targeting pancreatic cancer.
“C3 was chosen because of its ability to meet aggressive timelines,
while providing the highest levels of expertise and quality”
OncoVent, a joint venture between Shenzhen Hepalink Pharmaceutical Co.
and Canada-based OncoQuest, began negotiations with C3 after its drug
candidate had produced positive pre-clinical data for a combinatory
immunotherapy targeting pancreatic cancer. C3 was ultimately awarded the
contract and will complete the work at its Minneapolis-based cGMP
"C3 was chosen because of its ability to meet aggressive timelines,
while providing the highest levels of expertise and quality," said
OncoVent CEO, Dr. Y. Eric Shi. "We hope this is the beginning of a long
relationship that results in saving many lives."
C3 is headquartered in a 33,000 square foot facility that houses
corporate offices, bioreactor manufacturing operations, GMP-compliant
laboratory space, and a distribution center.
“It's an honor to be selected to support OncoVent’s immunotherapy
development,” said Christiaan Engstrom, President at C3. “We look
forward to leading the production of a product we hope will have global
About Cell Culture Company (C3)
Cell Culture Company is revolutionizing the quality, scalability and
predictability of diagnostic and therapeutic mammalian protein
production. For over 30 years, Cell Culture Company has been delivering
GMP production solutions and services from pre-clinical to commercial in
mg to kg quantities.
C3 delivers value to the BioPharmaceutical Industry by:
Decreasing production risk with single-use, closed systems
Increasing speed to market by reducing validation requirements
Improving cell health and quality via innovative perfusion bioreactor
Reducing production costs including capital expenditures, labor,
facilities and materials
About the Product: Anti-MUC1 MAb-AR20.5
Anti-MUC1 MAb-AR20.5 is a novel immunotherapeutic drug for
investigational use in the treatment of patients with malignancies
expressing the tumor-associated antigen known as MUC1. MAb-AR20.5 binds
with high affinity to MUC1, recognizing the tandem repeat peptide
sequence DTRPAP of the high molecular weight MUC1 glycoprotein. MUC1 is
expressed on many adenocarcinomas including pancreatic, breast, lung,
colon and prostate, as well as in multiple myeloma, and this epitope
uniquely exposed in malignant cells.
A Phase I clinical study in MUC1 expressing cancers has established
bioactivity associated with dose and a favorable safety profile.
OncoQuest is developing this antibody in conjunction with OncoVent for
the treatment of pancreatic cancer.
Forward Looking Statements
This press release includes forward-looking statements. These statements
are based upon current beliefs, expectations and assumptions. The
information in this release is provided only as of the date of this
release and the company undertakes no obligation to update any
forward-looking statements contained in this release based on new
information, future events, or otherwise, except as required by law.